Biological
NVX-CoV2373 adjuvated lipid nanoparticle clinical trials
Also written NVX-CoV2373 and TAK-019.
- studies test it
- 20
- open now
- 1
- in phase 3
- 10
- first study started
- 2020
Keep track of what changes. Save the NVX-CoV2373 adjuvated lipid nanoparticle studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 7
- Phase 3
- 10
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 17
Who runs them
Industry 16 · Other 4
Novavax (12) · Takeda (2) · Marcel Curlin (1) · Sarang K. Yoon, DO, MOH (1) · University of Wisconsin, Madison (1) · Tan Tock Seng Hospital (1) · Cogna Technology Solutions LLC (1) · Sanofi (1)
Often tested with
Tested in the same studies.
Influenza Vaccines (1) · Mivalsecovatein (1) · BBV152 COVID-19 vaccine (1)
Studies
Open first, then newest update. How each study uses NVX-CoV2373 adjuvated lipid nanoparticle is read from its arms, and is right about nine times in ten.
Testing it · 20
- Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19RecruitingPhase 4SanofiNCT07861542Written as Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineCompletedPhase 3NovavaxNCT06291857Written as Novavax COVID-19 Vaccine
- Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United StatesCompletedPhase 4NovavaxNCT06633835Written as protein subunit: Novavax COVID-19 vaccine
- Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsCompletedPhase 2/3NovavaxNCT05468736Written as SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsCompletedPhase 3NovavaxNCT05463068Written as NVX-Cov2373
- COVID-19 ReactogenicityActive, not recruitingPhase 4Marcel CurlinNCT07051031Written as Nuvaxovid (NVX-CoV2705)
- The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 InfectionCompletedPhase 4Sarang K. Yoon, DO, MOHNCT06065176Written as Novavax COVID-19 vaccine (2023-2024 formula XBB containing)
- Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed PopulationsCompletedPhase 2University of Wisconsin, MadisonNCT06027229Written as NVX-CoV2372
- Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesCompletedPhase 3NovavaxNCT05875701Written as NVX-CoV2373
- A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomCompletedPhase 3NovavaxNCT04583995Written as SARS-CoV-2 rS/Matrix M1-Adjuvant
- Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS VaccinesCompletedPhase 2/3NovavaxNCT05925127Written as NVX-CoV2373 (5μg)
- A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)CompletedPhase 3TakedaNCT05299359Written as TAK-019
- Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]CompletedPhase 4Tan Tock Seng HospitalNCT05142319Written as Nuvaxovid
- Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesCompletedPhase 3NovavaxNCT05372588Written as NVX-Cov2373
- A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2CompletedPhase 3NovavaxNCT04611802Written as SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- Phase 3 Boosting Study for the SARS-CoV-2 rS VaccineCompletedPhase 3Cogna Technology Solutions LLCNCT05249816Written as NVX-CoV2373
- A Study of TAK-019 in Healthy Japanese Adults (COVID-19)CompletedPhase 1/2TakedaNCT04712110Written as TAK-019
- Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M AdjuvantCompletedPhase 1/2NovavaxNCT04368988Written as SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1
- A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)CompletedPhase 2NovavaxNCT05112848Written as NVX-CoV2373
- A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African AdultsCompletedPhase 2NovavaxNCT04533399Written as SARS-CoV-2 rS/Matrix-M1 Adjuvant
Codes
What other systems call NVX-CoV2373 adjuvated lipid nanoparticle · ClinicalTrials.gg INT001483
- MeSH (NLM) C000711928NVX-CoV2373 adjuvated lipid nanoparticleConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2SCD8Q63PFNVX-COV2373 ADJUVATED LIPID NANOPARTICLEOne source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711928 | NVX-CoV2373 adjuvated lipid nanoparticle | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2SCD8Q63PF | NVX-COV2373 ADJUVATED LIPID NANOPARTICLE | One source NLM |
Also registered as nvx-cov2373 (UNII UK9AK2IN1P).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.